Credit Agricole S A Bluebird Bio, Inc. Transaction History

Credit Agricole S A

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $48,051 - $89,775	-4,275 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$16.59 - $33.89 $234,914 - $479,882	-14,160 Reduced 76.81%	4,275 $129,000
Q4 2020 Feb 12, 2021	BUY	$27.5 - $37.92 $384,037 - $529,552	13,965 Added 312.42%	18,435 $798,000
Q2 2020 Aug 13, 2020	SELL	$27.12 - $45.97 $7,322 - $12,411	-270 Reduced 5.7%	4,470 $273,000
Q1 2020 May 14, 2020	SELL	$26.16 - $63.5 $224,714 - $545,465	-8,590 Reduced 64.44%	4,740 $218,000
Q4 2019 Feb 12, 2020	SELL	$46.96 - $61.67 $52,125 - $68,453	-1,110 Reduced 7.69%	13,330 $1.17 Million
Q3 2019 Nov 08, 2019	BUY	$59.47 - $93.1 $346,115 - $541,842	5,820 Added 67.52%	14,440 $1.33 Million
Q1 2019 May 14, 2019	BUY	$64.44 - $104.11 $148,212 - $239,453	2,300 Added 36.39%	8,620 $1.36 Million
Q4 2018 Feb 13, 2019	BUY	$59.1 - $93.26 $23,640 - $37,304	400 Added 6.76%	6,320 $628,000
Q3 2018 Nov 13, 2018	BUY	$88.86 - $117.49 $22,215 - $29,372	250 Added 4.41%	5,920 $864,000
Q2 2018 Aug 10, 2018	BUY	$99.64 - $127.59 $564,958 - $723,435	5,670 New	5,670 $891,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $29.3M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Credit Agricole S A, based on Form 13F filings with the SEC.

Stay updated on Credit Agricole S A with notifications on news.